Fatty Acid Amide Hydrolase (FAAH) Inhibitors - Pipeline Insights, 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 30, 2018--The “Fatty Acid Amide Hydrolase (FAAH) Inhibitors- Pipeline Insights, 2018” report has been added to ResearchAndMarkets.com’s offering.
This report outlays comprehensive insights of present scenario and growth prospects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor.
A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.
This report provides detailed analysis of 5+ active products with more than 5 companies involved. Two of the key players include PF-04457845 of Spring Works Therapeutics and JNJ-42165279 of Janssen.
Products covered by PhasePhase II Pre-clinical Inactive (Dormant and Discontinued)
Overview of pipeline development activities for Fatty Acid Amide Hydrolase (FAAH) InhibitorsPipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Therapeutic segmentation of products for Fatty Acid Amide Hydrolase (FAAH) Inhibitors. The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.
ScopeProvides an overview of therapeutic pipeline activity for Fatty Acid Amide Hydrolase (FAAH) Inhibitors across the complete product development cycle including all clinical and non-clinical stages It comprises of detailed profiles of Fatty Acid Amide Hydrolase (FAAH) Inhibitors therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Fatty Acid Amide Hydrolase (FAAH) Inhibitors
Key Topics CoveredOverview Introduction Oleamide and Anandamide Function of Fatty acid amide hydrolase (FAAH) Structure of FAAH Mechanism of Action of FAAH Fatty acid amide hydrolase (FAAH) Inhibitor Future Scope for FAAH Inhibitor Emergence of FAAH Inhibitors Pipeline Therapeutics (Active Products) Pipeline Therapeutics (Inactive Products) Comparative Analysis Mid Stage Products (Phase II) Comparative Analysis JNJ 42165279: Janssen Product Description Research and Development The list continues.. Early Stage Products (Phase I) Comparative Analysis Pre-clinical and Discovery Stage Products Comparative Analysis Therapeutic Assessment: Active Products Assessment by Stage and Product Type Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Inactive Products Comparative Analysis Appendix
Companies FeaturedExxel Phrma Janssen MAKscientific Pfizer Scythian Biosciences Bial pharmaceuticals Infinity Pharmaceuticals Iron Wood Pharma Johnson and Johnson Leadiant Biosciences Makscientific Merck Pfizer Renovis Sanofi Vernalis
For more information about this report visit https://www.researchandmarkets.com/research/vhl4k5/fatty_acid_amide?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005613/en/
Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs ,Enzymes
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 07/30/2018 12:56 PM/DISC: 07/30/2018 12:56 PM